GOVX Research and Charts

GOVX - Geovax Labs Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-05-09)

Last 0.93	Change ⇓ -0.04 (0.00%)	Volume 117,200
	Open 0.98	High 0.98	Low 0.92

8EMA (Daily) 0.96	40EMA (Daily) 1.13	50EMA (Daily) 1.21	STO (Daily) 55.238	MACD Hist (Daily) 0.041
8EMA (Weekly) 1.086	40EMA (Weekly) 1.85	50EMA (Weekly) 3.59	STO (Weekly) 12.738	MACD Hist (Weekly) -0.085


Company Profile
Geovax Labs Inc is US-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform. The development programs of the company focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The product pipeline includes HIV-Clade B Preventive Vaccine, HIV-Clade B Immunotherapy, Hemorrhagic Fever Vaccines, Zika Vaccine, Malaria vaccine, and Cancer Immunotherapy.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.